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Abbreviations  
C3b-Bb, C4b-C2a C5 convertases  
C5a   complement C5a anaphylatoxin 
C5aRs   complement C5a receptors 1 and 2 
C5b-9  complement product of distal complement pathways 
IF  immunofluorescence  
KO knockout 
MAC  membrane attack complex, C5b-9 
Na+/K+-ATPase   sodium (Na+) and potassium (K+)-ATPase  
NCX   Na+/Ca2+ exchanger 
NETs   neutrophil extracellular traps 
PMNs   polymorphonuclear leukocytes (neutrophils) 
rmC5a  recombinant mouse C5a 
SERCA2   sarco/endoplasmic reticulum Ca2+-ATPase 
 
Abstract  
 In this Mini-Review, we describe the molecular mechanisms in polymicrobial sepsis 
that lead to a series of adverse events including activation of inflammatory and 
prothrombotic pathways, a faulty innate immune system, and multiorgan dysfunction. 
Complement activation is a well-established feature of sepsis, especially involving 
generation of C5a and C5b-9, along with engagement of relevant receptors for C5a 
Activation of neutrophils (PMNs) by C5a leads to extrusion of DNA, forming neutrophil 
extracellular traps (NETs) which contain myeloperoxidase and oxidases, along with 
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extracellular histones. Generation of the distal complement activation product, C5b-9 
(known as the membrane attack complex, MAC), also occurs in sepsis. C5b-9 activates the 
NLRP3 inflammasome, which damages mitochondria, together with appearance in plasma of 
IL-1β and IL-18. Histones are strongly proinflammatory as well as being prothrombotic, 
leading to activation of platelets and development of venous thrombosis. Multiorgan 
dysfunction is also a feature of sepsis. It is well known that septic cardiomyopathy, which, if 
severe, can lead to death. This complication in sepsis is linked to reduced levels in 
cardiomyocytes (CMs) of three critical ATPase proteins. The reductions in these three key 
proteins are complement- and histone-dependent. Dysfunction of these ATPases is linked to 
the cardiomyopathy of sepsis. These data suggest novel targets in the setting of sepsis in 
humans.  
 
1. Introduction 
Infectious sepsis in North America involves more than 500,000 humans annually [1], 
with a death rate of ~40% depending on the severity of sepsis [2]. These infections chiefly 
are triggered by bacteria, but viruses, fungi and protozoa may also cause sepsis [3, 4]. In 
spite of extensive research in septic animals and humans, there has yet to be a Federal Drug 
Administration (FDA)-approved drug specifically for treatment of sepsis. Supportive care 
such as fluid resuscitation, broad spectrum antibiotics delivered early, and safer techniques 
for mechanical ventilation have improved clinical outcomes in septic patients [5]. This Mini-
Review describes information gained from the study of polymicrobial sepsis in mice, which is 
providing new insights into interventions that may pave the way for new strategies for 
treatment of humans with sepsis.  
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 It is important to mention the extent to which genomic studies in humans and in 
mice have influenced our understanding of sepsis. A few years ago, a consortium of 
investigators compared genomic analysis using blood leukocytes from humans and mice 
that had experimental sepsis, burn injury and other “inflammatory stresses”. The report by 
Seok et al [6] concluded that “genomic responses in mouse models poorly mimic human 
inflammatory diseases”. This led to many reports in newspapers, suggesting that use of mice 
was essentially irrelevant for trying to understand human sepsis. In 2015, a group from 
Japan, using the same database came to an opposite conclusion, that “genomic response in 
mouse models greatly mimic human inflammatory diseases” [7]. This controversy has, as of 
2018, not been resolved and represents a troubling problem, especially since both articles 
were published in a respected scientific journal (Proceedings of the National Academy of 
Sciences of USA). As of now, there is no consensus that genomic analysis of mice with sepsis 
can reliably be extrapolated to humans with sepsis, and this has caused large pharma 
companies to avoid research investment in the field of sepsis, whether the activity involves 
mice with polymicrobial sepsis or septic humans. On the other hand, it should be 
emphasized that the use of septic mice has allowed studies that could not be done in 
humans with sepsis (such as measurements of regulatory proteins in cardiomyocytes). 
Septic mice have provided important information on signaling pathways and how these 
pathways can be manipulated to reduce organ dysfunction in sepsis, at least in mice. Finally, 
studies show a link between complement product of C5a and adverse outcomes in septic 
mice and in septic humans. Use of knockout (KO) mice (lacking C5a receptors, C5aRs) have 
been shown to be protected from adverse events in the heart developing in sepsis [8, 9]. 
This emphasizes that certain manipulations can be done in septic mice that add important 
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information on how sepsis causes organ dysfunction and might have application in septic 
humans. 
 
2. Role of Complement in Polymicrobial Sepsis (Figure 1) 
 Polymicrobial sepsis has been frequently used for the study of sepsis in rats and 
mice, especially sepsis induced by cecal ligation and puncture (CLP), which often closely 
mimics the clinical picture of humans with sepsis [10-13]. The procedure, originally 
described nearly 40 years ago [14], has been widely used, in part due to the availability of 
KO mice. The technique involves a through-and-through puncture of the cecum, with 
extrusion of small amounts of feces into the peritoneal cavity. The intensity of sepsis can be 
controlled by the numbers of punctures and the size (gauge) of the needle [15]. 
“Polymicrobial” refers to the presence of both aerobic and anaerobic bacteria that appear in 
the peritoneal cavity and in blood of septic mice [16]. The polymicrobial sepsis model has 
rarely been used in larger animals or subhuman primates, in part because in such cases an 
ICU setting would have to be available, requiring animal care around the clock, all of which 
would result in exceptionally high operating costs. In addition, obtaining institutional 
approval for use of CLP in subhuman primates would be highly problematic.   
 Complement activation products and relevant receptors involved in polymicrobial 
sepsis are described in Figure 1. The onset of sepsis triggers activation of several of the 
complement pathways, with the “classical” and the “alternative” pathways being activated 
in polymicrobial sepsis [17]. It remains to be determined what precisely triggers activation 
of these pathways. The C5 convertase in the classical pathway involves C4b and C2a, while 
in the alternative pathway C3b and Bb represent the C5 convertase. In either case, C5a and 
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C5b are generated. It is not clear what triggers complement activation in infectious sepsis 
involving mice with polymicrobial sepsis or septic humans. It is well established that Gram 
negative bacteria often activate complement by interaction via the lectin pathway. This 
features the mannose-binding lectin interacting with carbohydrates on the surfaces of 
bacteria. Related to the innate immune system, there are many pattern-associated 
molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) that can 
activate complement. For example, bacterial lipopolysaccharide (LPS) from Gram negative 
bacteria is a well-known bacterial product that activates the alternative complement 
pathway. LPS interacts with TLR2 and TLR4 causing activation of signaling pathways in a 
variety of cells (Figure 3). Finally, certain Gram positive bacteria (e.g. Staph. aureus) secrete 
proteins that block complement activation molecules.  The third pathway (“lectin” 
pathway), is sometimes the chief pathway of complement activation in bacterial-induced 
sepsis [17]. Whatever pathway is being triggered, there is appearance of C5a, the powerful 
anaphylatoxin, which reacts with its receptors (C5aR1 and C5aR2) that are especially 
prevalent on neutrophils (PMNs) [18, 19]. A consequence of these events is strong 
activation of PMNs and, to a lesser extent, macrophages [18, 19]. Activated PMNs release 
long strands of DNA forming neutrophil extracellular traps (NETs) along with release of 
histones as well as products of PMN-specific granules (myeloperoxidase, proteases, etc.) 
[20-22]. Histones (H1, H2A, H2B, H3, H4) are molecules with potent proinflammatory and 
prothrombotic activities inducing biological responses [23]. As will be emphasized in Figure 
2, extracellular histones play key effector roles in human and mouse sepsis. Histones can 
cause diffuse vascular and epithelial cell damage and play important roles in multiorgan 
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dysfunction that develops in sepsis. Downstream complement activation also results in 
generation of C5b-9 (membrane attack complex, MAC) (Figure 3).  
It is important to emphasize that complement activation via either the classical or 
the alternative pathway results in generation of C5 convertase which generates both C5a 
and C5b. C5a reacts with C5aRs on PMNs, causing production of NETs, which release 
histones that have powerful proinflammatory functions. Generation of C5b interacts with 
C6, C7, C8 and C9 to form C5b-9. This complex is known to activate the NLRP3 
inflammasome which results in inflammasome activation, mitochondrial damage and 
release of IL-1β and IL-18 which are powerful proinflammatory cytokines. The NLRP3 
inflammasome in its precursor mode, exists in a variety of cells (PMNs, macrophages, 
cardiomyocytes, astrocytes, etc.). Briefly, the inflammasome protocol consists of the 
“priming” phase in which cells are exposed to LPS (100 ng/ml) for 4 hr at 37C. This results in 
very little release of IL-1β. Thereafter, the cells are exposed to 1 mM ATP for 45 min, which 
serves as an “activator”, resulting in very substantial release of IL-1β [22, 23]. Suresh et al 
also demonstrated that complement-mediated “bystander” damage, during the 
phagocytosis of complement-opsonized particles in macrophages, initiates NLRP3 
inflammasome activation, resulting in caspase-1 activation and IL-1β and IL-18 secretion 
[24]. To an extent, complement-dependent activation or inflammasome activation can 
cause acute cellular and organ dysfunction via C5a and C5b-9 by the mechanisms described 
above.  Such adverse events can occur whenever complement or inflammasome activation 
occurs. In this sense, cell damage does not occur in a targeted manner, but in the vicinity of 
where activation of complement or inflammasome is occurring, such that a variety of cells 
may be damaged. 
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 Regarding bacteria and the complement system, it is well established that Gram 
positive bacteria, such as Staph. aureus, are resistant to effects of complement activation 
while Gram negative bacteria are sensitive to effects of complement activation. For 
instance, some Staph. aureus bacteria are resistant to methicillin and may pose a grave 
danger to individuals. It should also be emphasized that many Gram negative bacteria 
release LPS which react with TLRs (2, 3, 4, 9) that in the setting of sepsis may collectively 
contribute to the adverse events in infectious sepsis [25]. Complement activation products 
such as C3b and iC3b promote phagocytosis of bacteria and their intracellular killing by 
PMNs and macrophages, often via NADPH oxidase and its products, oxygen-derived free 
radicals [26, 27]. In addition, as mentioned above, MAC also has cytolytic effects on bacteria 
via MAC or via the lectin and NLRP3 inflammasome pathways. Bacteria can also activate the 
lectin pathway of complement, resulting in antibacterial effects described above. It should 
also be pointed out that certain Gram positive bacteria (such as Staph. aureus) release 
peptides that block complement activation or complement activation products [28]. 
 The issue of whether complement complexes such as C5b-7 or C5b-8 assert cell 
damaging activity has by-in-large not been convincingly shown in experimental studies. A 
recent study by Morgan’s group showed that in the absence of C9, sublytic MAC cannot be 
generated so cannot drive inflammation and apoptosis in human lung epithelial cells as 
found by studying cytokine production, NLRP3 inflammasome activation, cytosolic Ca2+ 
increase, mitochondrial dysfunction and cytochrome c release [29]. It should be mentioned 
that most of the published information related to C5b-7 and C5b-8 fails to show damaging 
effects on mammalian cells. 
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3. Mechanisms of Histone-induced Cell Damage in Sepsis (Figure 2)  
Figure 2 describes our recent work that has defined signaling pathways occurring in 
the heart after onset of CLP-induced sepsis. A major event is activation of PMNs by C5a, 
resulting in appearance of NETs and extracellular histones. It has been established that 
histones bind to toll-like receptors (TLRs) in various cell types [30-33], including 
cardiomyocytes (CMs) [34]. This results in activation of platelets and development of 
thrombosis. Another major event occurring in the presence of extracellular histones is 
activation of PMNs and macrophages, causing generation of intracellular oxidants (reactive 
oxygen species, ROS) in a variety of cells, as well as appearance of proinflammatory peptides 
(cytokines, chemokines and other factors), all of which cause cell dysfunction and, often, 
apoptosis, especially in the setting of infectious sepsis [35]. Other damaging features of 
histones is that they can directly cause cell damage and apoptosis and are very 
prothrombotic and proinflammatory [36]. Several studies showed that histones bind to 
different TLRs (mainly TLR2 and TLR4) and interact with these receptors on various cell types 
[30-33, 37]. It should be mentioned that depending on the experimental setting and cell 
lines used, there are additional data about TLR2 or TLR4 being activated by histones. The 
study by Xu et al showed TLR4, but not TLR2, was the major receptor for a histone-induced 
cytokine inflammatory response after histone infusion into TLR4 KO mice [30].  The study by 
Ekaney et al [38] also showed that blocking TLR4 resulted in decreased cellular cytotoxicity 
on human endothelial cells (as measured by lactate dehydrogenase measurement and 
propidium iodide staining). It has been shown that combination of TLR2 and TLR4 blocking 
antibodies suppressed the cytotoxic and antiangiogenic effects on endothelial cells [39]. We 
have also found the macrophages from double TLR2 and TLR4 KO mice had dramatically 
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reduced IL-1β release induced by inflammasome protocol after the exposure to individual 
histones compared to single KO of TLR2 or TLR4 [23]. 
 
4. Molecular Basis of Cardiac Dysfunction Developing during Polymicrobial Sepsis (Figure 3)  
 Figure 3 describes how infectious sepsis activates a series of signaling pathways that 
have detrimental effects on cardiac function in mice.  Initially, the mitogen-activated protein 
kinase (MAPK), especially p38, and Akt signaling pathways are activated, followed by 
increased plasma levels of various cytokines, chemokines and extracellular histones. The 
results of these events caused significant dysfunction of CMs. The basis for defects in CM 
function was linked to p38 activation, since a water soluble inhibitor of p38 prevented 
development of sepsis-induced heart dysfunction, as defined by ECHO-Doppler parameters 
[40]. Reasons for septic cardiomyopathy could be traced to defects in Na+/K+-ATPase, which 
is critical for effective action potentials in CMs and in other cell types. Defects in SERCA2 and 
NCX led to diastolic buildup of [Ca2+]i in CMs in a manner that was associated with the 
inability to clear cytosolic [Ca2+]i in CMs during diastole [8, 9, 34]. Such events caused 
substantial dysfunction and apoptosis of CMs. We believe these events likely occurred in 
other organs (brain, liver, lungs, etc.), resulting in multiorgan dysfunction in sepsis. Based on 
this information, blocking p38 activation might be a strategy to prevent cardiac dysfunction 
developing in sepsis in humans. 
  
5. Conclusions 
 The data in Figures 1, 2 and 3 emphasize the appearance of complement activation 
products and histones during sepsis, leading to cardiac dysfunction. Since C5a is such a key 
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factor in many induced defects developing in septic cardiomyopathy, in vivo blockade of 
either C5a or C5aRs in septic mice would be an obvious potential therapeutic strategy. Such 
inhibitors are not currently available but are under development. In severe sepsis in 
humans, most events leading to lethality occur during the first 3-5 days after onset of sepsis, 
especially in elderly septic patients. Therapeutic application of C5a or signaling pathway 
inhibitors would only be for a limited period of time (3-5 days). Currently, several 
pharmaceutical companies are developing small molecular weight compounds that block 
C5a or C5, although clinical trials have not yet been done in order to assess safety and 
efficacy of these compounds. In terms of blockade of C5b-9, there do not yet appear to be 
any FDA-approved drugs, except perhaps antibody to C5, that result in blockade of 
generation of C5b-9. However, the use of mAb to human C5 (eculizumab), which should 
block generation of C5a and C5b-9, is also associated with predilection to development of 
meningococcal meningitis. In some diseases affecting the complement system, such as 
paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome 
(aHUS), clinical trials showed that eculizumab is effective and safe [41]. However, in the 
setting of infectious sepsis associated with bacteremia, use of anti-C5 would likely face a 
very high barrier for FDA approval that would require very expensive clinical trials on the 
safety of such an intervention. In the short term, it seems unlikely that FDA approval would 
be granted. Development of small molecule inhibitors than block the activation epitope of 
C9 would be an attractive strategy to prevent the biological activity of C5b-9. There are 
currently mAbs that block the epitope of activated C9, but this mAb has not been used in 
humans. Targeting IL-1 produced by the activated NLRP3 inflammasome has already been 
tried unsuccessfully in septic humans using a compound IL-1 (IL-1r antagonist, IL-1ra 
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[anakinra]) [42, 43]. One study in septic mice applying combination therapy targeting IL-1 
and IL-18 showed promising data [44]. Vanden Berghe et al, using CLP or LPS-induced 
endotoxemia in mice, showed that only the combined neutralization of IL-1ra and anti-IL-18 
conferred complete protection against endotoxin-induced lethality in the mice. They also 
found similar results after applying the mice genetically deficient for both IL-1β and IL-18 
[44]. Although clinical trials using these combination therapies would be needed to confirm 
the mice data, the results of the failed clinical trials using blockade of IL-1 have discouraged 
additional clinical trials featuring blockade of IL-1RA. It is important to suggest that, beyond 
sepsis, blocking C5a or its receptors or C5b-9 might have relevance in many other situations 
in humans, such as acute cardiac ischemia, acute lung injury, autoimmune diseases (e.g. 
rheumatoid arthritis, systemic lupus erythematosus) and early allograft rejection.  
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Figure Legends 
Figure 1.  Sequence of events developing during infectious sepsis and the important role of 
complement activation, which results in generation of two major products, C5a and C5b-9 
(membrane attack complex). C5a activates polymorphonuclear leukocytes (neutrophils) that 
form NETs which release extracellular histones and proinflammatory peptides. C5b-9 
activates the NLRP3 inflammasome, leading to release of two potent cytokines, IL-1β and IL-
18. 
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Figure 2.  Infectious sepsis leads to the appearance of extracellular histones which interact 
with TLR2 and TLR4.  This results in activation of the clotting system with thrombus 
formation, activation of neutrophils and macrophages that trigger a series of 
proinflammatory outcomes, together with ensuing cell damage and apoptosis. 
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Figure 3.  Events in infectious sepsis that cause the cardiomyopathy of sepsis, which is 
defined as contractile and relaxation defects in cardiomyocytes (CMs). The outcomes can be 
traced in MAPK (p38) and Akt activation in CMs, leading to cardiac dysfunction.  These 
defects are associated with defective action potentials (reduced Na+/K+-ATPase) in CMs, 
together with reduced activity of [Ca2+]i regulatory proteins, SERCA2 and NCX. 
 
 
 
